RxDoctor Payments Data

Ranvir Singh, MD

Gastroenterology · Cumming, GANPI 1639289465

Payments from drug & device makers

$5,671in general payments, 2019–2025

Across 266 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sanofi$413
  • Regeneron Healthcare Solutions, Inc.$394
  • Johnson & Johnson$384
  • Takeda Pharmaceuticals U.S.A., Inc.$325
  • Pfizer$246
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,55798%
  • Education$1142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,671 in reported general payments places this provider in the 60th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$86,943
Medicare patients
317
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab16$142,148
LinzessLinaclotide39$32,639
CreonLipase/Protease/Amylase12$27,331
Dexlansoprazole DrDexlansoprazole22$10,255
Ursodiol13$6,906
Famotidine300$4,295
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates50$3,374
Lubiprostone12$2,470
Pantoprazole Sodium157$2,393
CholestyramineCholestyramine (With Sugar)21$1,229
Omeprazole100$863
Esomeprazole Magnesium17$704
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl28$457
Ondansetron OdtOndansetron22$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,922$59,96951 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →